Acadian Asset Management’s Cytek Biosciences CTKB Stock Holding History
Bought
Maintained
Sold
Other funds holding CTKB
Acadian Asset Management's CTKB Position: Q3 2026 in Review
Acadian Asset Management increased its Cytek Biosciences (CTKB) stake by 98% in Q3 2026, buying an estimated $6.37M and bringing the position to 2,718,890 shares worth $16.2M. The position accounts for 0.02% of the portfolio, ranked #461.
Acadian Asset Management first reported a position in CTKB in Q1 2025 and has held it in 7 quarters since. 152 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.
- Acadian Asset Management held 2,718,890 shares of Cytek Biosciences worth $16.2M as of Q3 2026.
- Acadian Asset Management bought 1,342,842 Cytek Biosciences shares in Q3 2026, an estimated $6.37M.
- Cytek Biosciences made up 0.02% of Acadian Asset Management's portfolio in Q3 2026, its #461 holding.
- Acadian Asset Management first reported a position in Cytek Biosciences in Q1 2025 and has held it in 7 quarters since.
- 152 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.
Based on Acadian Asset Management's 13F filing for Q3 2026, filed 9 Nov 2026.